June 28, 2013

Genzyme Receives Positive CHMP Opinion for LEMTRADATM (alemtuzumab) in Europe

CHMP also Recommends NAS Designation for AUBAGIO® (teriflunomide) Following Positive Opinion on Approval in March 2013

Positive Opinions Set Stage for Introduction of Two New Genzyme Therapies for Multiple Sclerosis in Europe

 

Genzyme Receives Positive CHMP Opinion for LEMTRADATM (alemtuzumab) in Europe
CHMP also Recommends NAS Designation for AUBAGIO® (teriflunomide) Following Positive Opinion on Approval in March 2013

Paris, France – June 28, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of LEMTRADATM (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.